The Cost-effectiveness of Vaccination Against Lyme Disease

Shadick, Nancy A.; Liang, Matthew H.; Phillips, C I; Fossel, Karin; Kuntz, Karen M.

doi:10.1001/archinte.161.4.554

Cited by 53 publications

(43 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is the most common vector-borne disease in the North America and Europe, and remains an emerging disease of considerable importance due to its potentially serious cardiac, neurological, and arthritic sequelae [3][4][5][6][7][8][9][10]. The need for a Lyme disease vaccine has been clearly established [11,12]. The outer surface…”

Section: Introductionmentioning

confidence: 99%

Construction and analysis of variants of a polyvalent Lyme disease vaccine: Approaches for improving the immune response to chimeric vaccinogens

Earnhart

Marconi

2007

Vaccine

View full text Add to dashboard Cite

There is currently no Lyme disease vaccine commercially available for use in humans. Outer surface protein C (OspC) of the Borrelia has been widely investigated as a potential vaccinogen. At least 38 OspC types have been defined. While the antibody response to OspC is protective, the range of protection is narrow due to the localization of protective epitopes within OspC type-specific domains. To develop a broadly protective vaccine, we previously constructed a tetravalent chimeric vaccinogen containing epitopes from OspC types A, B, K, and D. While this construct elicited bactericidal antibody against strains bearing each of the four OspC types, its solubility was low, and decreasing IgG titer to epitopes near the C-terminus of the construct was observed. In this report, construct solubility and immunogenicity were increased by dialysis against an Arg/Glu buffer. We also demonstrate the immunogenicity of the construct in alum. To further optimize epitope-specific immune responses, several constructs were generated with differing epitope organization or with putative C-terminal protective motifs. Analyses of murine antibody titers and isotype profiles induced by these constructs revealed that while the C-terminal tags did not enhance antibody titer, specific epitope reorganization and reiteration did. These analyses provide important information that can be exploited in the development of chimeric vaccinogens in general.

show abstract

Section: Introductionmentioning

confidence: 99%

Construction and analysis of variants of a polyvalent Lyme disease vaccine: Approaches for improving the immune response to chimeric vaccinogens

Earnhart

Marconi

2007

Vaccine

View full text Add to dashboard Cite

show abstract

“…The outer surface protein A (OspA)-based LymeRix vaccine, introduced in 1998, was pulled from the market in 2002 due to poor sales, possibly traced to concerns over vaccine-induced arthritis (21). There is a pressing need for the development of an effective, safe, and broadly protective Lyme disease vaccine (29,40).…”

mentioning

confidence: 99%

OspC Phylogenetic Analyses Support the Feasibility of a Broadly Protective Polyvalent Chimeric Lyme Disease Vaccine

Earnhart

Marconi

2007

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Three doses of this vaccine had 76% protective effi cacy against defi nite Lyme disease and 100% against asymptomatic infection. 4 According to several models, [5][6][7] the vaccine was cost eff ective for individuals at high risk of infection. However, in early 2002, LYMErix was voluntarily withdrawn from the market, merely 38 months after its approval.…”

Section: Lyme Disease Vaccination: Are We Ready To Try Again?mentioning

confidence: 99%

Lyme disease vaccination: are we ready to try again?

Lantos¹

2013

The Lancet Infectious Diseases

View full text Add to dashboard Cite

The Cost-effectiveness of Vaccination Against Lyme Disease

Abstract: Vaccination against Lyme disease appears only to be economically attractive for individuals who have a seasonal probability of Borrelia burgdorferi infection of greater than 1%.

Cited by 53 publications

References 35 publications

Construction and analysis of variants of a polyvalent Lyme disease vaccine: Approaches for improving the immune response to chimeric vaccinogens

Construction and analysis of variants of a polyvalent Lyme disease vaccine: Approaches for improving the immune response to chimeric vaccinogens

OspC Phylogenetic Analyses Support the Feasibility of a Broadly Protective Polyvalent Chimeric Lyme Disease Vaccine

Lyme disease vaccination: are we ready to try again?

Contact Info

Product

Resources

About